Total Solutions for the Development of Bispecific Antibodies

Immune Cell Engagers (ICEs) represent one of the most typical mechanisms of action for bsAbs, functioning primarily to bridge immune effector cells and tumor cells. One arm targets TAAs, while the other binds activating receptors on immune effector cells (such as T cells or NK cells). This dual engagement precisely recruits immune cells to the tumor site, bypassing MHC restriction and directly triggering immune-mediated cytotoxicity.

The Dual Signaling Pathway Modulation mechanism involves simultaneously targeting and regulating two distinct signaling pathways—or two different targets in the same pathway—to more effectively suppress tumor growth, proliferation, or angiogenesis, and to overcome therapeutic resistance.

The Immune Checkpoint Modulation mechanism involves simultaneously targeting two immune regulatory molecules to more effectively relieve immunosuppression or deliver costimulatory signals, thereby restoring and enhancing antitumor immune responses.

The Targeted Payload Delivery mechanism leverages the dual specificity of bsAbs to precisely deliver drugs, toxins, or other therapeutic molecules to target cells, thereby enhancing efficacy while minimizing off-target toxicity.

The Protein Assembly or Functional Substitution mechanism centers on mimicking the function of natural protein complexes or substituting for missing or directly dysfunctional proteins to restore normal physiological processes. For example, Emicizumab (FIXa × FX) mimics the function of the coagulation factor complex, thereby restoring clotting activity in patients with hemophilia.

To support BsAbs development from discovery to evaluation, we provide a comprehensive portfolio of assay kits covering TR-FRET, bridging ELISA, inhibitor screening, PK (pharmacokinetic) analysis, and biomarker ELISA kits. Built on high-quality target proteins, these kits feature high sensitivity, straightforward protocols, and broad compatibility, making them ideal for BsAbs screening, efficacy assessment, immune activity studies, and safety evaluation.

Functional validation is a critical component in the development of BsAb. To meet the needs for various cell models at different research stages, ACROBiosystems leverages its well-established cell engineering platform to develop a range of high-quality functional cell line products, including reporter cell lines, overexpression cell lines and gene knockout cell lines.

Anti-idiotypic antibodies are antibodies that target the variable region of another antibody to produce specific binding. Anti-idiotypic antibodies are widely used in the development of BsAbs. They can serve as critical reference reagents for immunogenicity assessments and enable the specific quantification of antibody drug levels in biological matrices, making them essential tools for pharmacokinetic studies.

ACROBiosystems is committed to providing high quality key reagents and related services required in the development of targeted therapeutic drugs. We provide a series of anti-idiotypic antibodies with high affinity, high specificity, and high sensitivity. To meet the more unique needs of our customers, we also provide a one-stop service, starting from antigen preparation to monoclonal / polyclonal anti-idiotype antibody and pharmacokinetic / immunogenicity test kit development.

ComboX is a universal product brand meticulously crafted by ACROBiosystems, converging a diverse and high-quality product portfolio to provide comprehensive solutions for scientific research. "Combo", symbolizing combination, reflects our integration of diversified products to meet your varied needs from basic research to biopharmaceutical development. "X", representing infinite possibilities, embodies our highly diverse universal product line and comprehensive reagent support spanning from single components to multifaceted systems.

ComboX is not merely a tool but a trusted partner on your research journey. We eagerly anticipate collaborating with you to unlock the mysteries of science and explore the boundless potential of biopharmaceutical development.

In BsAb development, the accuracy and reproducibility of analytical assays rely on a stable and efficient molecular capture system. The particle size, surface area, and coating uniformity of magnetic beads significantly influence binding efficiency and signal strength, while the quality of the surface-coupled proteins is a key determinant of overall assay performance.

Leveraging well-established biotinylated protein platform, ACROBiosystems has developed a series of high-performance biotin-labeled protein-conjugated magnetic beads. These are suitable for various experimental scenarios in BsAb research, including candidate screening, binding analysis, ELISA, and flow cytometry, providing highly sensitive and reproducible detection tools.

The development of BsAb relies on precise characterization of molecular interactions. Leveraging the Biacore and ForteBio Octet platforms, ACROBiosystems provides comprehensive molecular interaction analysis services for biopharmaceutical R&D, enabling bispecific antibody screening, functional assessment, and comparability evaluation.

BsAbs can simultaneously recognize two distinct targets, and their molecular architecture, tissue distribution, and clearance pathways often differ substantially from those of conventional monoclonal antibodies. The structural complexity of bispecific formats makes their in-vivo behavior difficult to predict. Variations in molecular designs—such as IgG-like formats, BiTEs, and CrossMabs—can lead to pronounced differences in half-life and clearance mechanisms. In addition, unequal affinities of the two binding arms may result in target-mediated, arm-dependent clearance. Therefore, comprehensive pharmacokinetic studies are essential to define a BsAb’s in-vivo exposure, metabolism, and elimination characteristics, thereby providing a scientific foundation for dose selection and dosing frequency.

To meet the complex development needs of BsAb programs, we offer end-to-end services ranging from antigen preparation to the development of monoclonal and polyclonal anti-idiotypic antibodies, as well as pharmacokinetics and immunogenicity assay kits.

Immunogenicity: according to regulatory guidance, drug immunogenicity is defined as the ability of a drug and/or its metabolites to elicit immune responses or immune-related events against the drug itself or associated proteins. Immunogenicity can have wide-ranging consequences. Unintended immune responses may neutralize the drug’s biological activity, trigger cross-reactivity with endogenous proteins, or induce adverse events such as allergic reactions or cytokine release syndrome. Clinically, the impact of immunogenicity varies: it may have no apparent effect on some patients, while in others it can significantly alter the drug’s pharmacokinetics, pharmacodynamics, safety, and efficacy.

ACROBiosystems provides customized services for immunogenicity assay kits tailored to your project needs!

Because blood serves as the primary medium for the absorption, distribution, metabolism, and excretion of drugs and their metabolites, the concentration of a drug in various tissues and body fluids is generally correlated with its blood concentration. As a result, changes in blood drug levels are highly representative and blood is the most commonly used sample matrix. To support preclinical and clinical pharmacokinetic studies of antibody drugs, it is crucial to design a precise and reliable analytical method for quantifying drug concentrations in blood.

ACROBiosystems provides drug concentration (PK) assay kits customized service tailored to your program needs.

During the development of bispecific antibodies, ELISA serves as a core analytical method for assessing drug activity, affinity, and in-vivo/in-vitro exposure levels. ACROBiosystems has a dedicated product R&D team and technical service team, and—supported by our extensive internal portfolio of proteins and antibodies—we have accumulated substantial experience and experimental data in analytical method development across multiple bioanalytical platforms.

We design scientifically robust study plans, develop efficient and reliable assay methods, and conduct comprehensive and accurate method validation tailored to specific project needs. We provide both ELISA testing services and custom ELISA kit development services for biopharmaceutical R&D customers.